Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 SCHOTT Continues to Expand U.S. Presence | Contract Pharma

What are you searching for?

Sign in
Breaking News

SCHOTT Continues to Expand U.S. Presence

Setting a strategic portfolio in the U.S. aims to capitalize on the world’s largest economy and capacity for innovation.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

SCHOTT, a specialty glass and international technology group, continues to expand its presence in North America to align operations and accelerate global profitability.
 
SCHOTT’s Pharmaceutical Systems business unit in Lebanon, PA contributed to the global COVID-19 response, increasing manufacturing capacity to meet the needs of vaccine makers. The Pennsylvania plant also supplies the growing demand of high-value products such as adaptiQ ready-to-use vials and EVERIC pure for highly potent drugs such as cancer medication. As part of a multimillion-dollar investment in the U.S. this past fiscal year, the facility underwent upgrades and expanded capacity for vial production.
 
Also, SCHOTT MINIFAB’s acquisition of Applied Microarrays Inc. (AMI) added cutting-edge biotech capabilities for diagnostics applications along with a production hub in Arizona.


SCHOTT MINIFAB has extensive bioscience capabilities across Australia, Europe and now in the USA. Image: SCHOTT MINIFAB
“Our flexibility and commitment to a strategy of innovation will only strengthen our U.S. operations moving forward. With seven production sites, one R&D center, a sales office, and roughly 1,000 employees in the U.S., SCHOTT is well established,” said Dr. Heinz Kaiser, board member at SCHOTT and responsible for the group’s business in North America. “Over the past several years, we have invested $60 million in the U.S., and additional investments will accelerate our strategy of profitable growth and allow us to concentrate our activities on markets where we expect strong, sustainable development.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics